Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC08/r + peginterferon alfa-2a + ribavirin in treatment-naive chronic hepatitis C genotype 1 (non-cirrhotic)
CTR20160370Phase 3Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jul 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of danoprevir in hepatitis C virus infection, sponsored by Ascletis Pharma Inc.. Started Jul 2016; status: completed.
02
Drugs
danoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on CTR20160370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160370.